Durvalumab vs Ipilimumab

## Durvalumab vs Ipilimumab: Overview

This comparison examines the pharmacological differences between **Durvalumab** and **Ipilimumab**.

## Mechanism of Action

**Durvalumab**: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

**Ipilimumab**: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

## Pharmacokinetics

**Half-life**: Durvalumab — 17 days; Ipilimumab — 14.7 days.

## Chemical Properties

**Type**: Durvalumab — Antibody; Ipilimumab — Antibody.